AACR23 – Is there an ADC renaissance on the horizon?
Orlando – the AACR annual meeting provides a window into future cancer drug development, and this year’s meeting is no exception.
As AACR23 comes to an end in sunny Orlando, we’re taking a closer look at the next generation of ADC’s in early development and some of the data presented at AACR23.
Companies are always looking for new ways to overcome resistance pathways or provide novel combination strategies. Will the next generation compounds in development lead to a continued renaissance in the ADC field?
There’s certainly plenty to think about if you are a new products or business development professional…
To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
